Evidence map›Paper›PMID 40099865›Full record

ReviewFuture microbiology2025

Reviving the past for a healthier future: ancient molecules and remedies as a solution to the antibiotic crisis.

Miguel Ángel Díaz-Guerrero, Israel Castillo-Juárez, Rimma Zurabian, Alejandra Valdez, Kokila Kota, Yuki Hoshiko, Ekaprana Ramesh, Mariano Martínez-Vazquez, Corina Diana Ceapă, Mariel Hernandez-Garnica and 2 more

Abstract readReview
In one paragraph

Review in Future microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Negamycin: Nature's Forgotten Antibiotic.ACS infectious diseases · 2026
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Miguel Ángel Díaz-GuerreroDepartamento de Microbiología y Parasitología, Facultad de Medicina, UNAM, Mexico City, Mexico.ORCID 0000-0002-7498-8117
Israel Castillo-JuárezConahcyt-Instituto de Ciencias Básicas e Ingeniería, Universidad Autónoma del Estado de Hidalgo, Mineral de la Reforma, Hidalgo, México.ORCID 0000-0001-6983-5565
Rimma ZurabianDepartamento de Microbiología y Parasitología, Facultad de Medicina, UNAM, Mexico City, Mexico.ORCID 0000-0003-0309-0585
Alejandra ValdezLaboratorio de Interacciones Microbianas, Planta Piloto de Procesos Industriales Microbiológicos, PROIMI, CONICET, San Miguel de Tucumán, Tucumán, Argentina.ORCID 0000-0002-3531-7281
Kokila KotaDepartment of Biology, Ramapo College of New Jersey, Mahwah, NJ, USA.
Yuki HoshikoDepartment of Health Science, School of Allied Health Sciences, Kitasato University, Sagamihara, Japan.ORCID 0009-0001-4356-5584
Ekaprana RameshDepartment of Biology, Ramapo College of New Jersey, Mahwah, NJ, USA.
Mariano Martínez-VazquezDepartamento de Química de Productos Naturales, Instituto de Química UNAM, Mexico City, Mexico.ORCID 0000-0002-8821-0648
Corina Diana CeapăLaboratory of Microbiology, Institute of Chemistry, National Autonomous University of Mexico, Mexico City, Mexico.ORCID 0000-0001-8661-4211
Mariel Hernandez-GarnicaDepartamento de Microbiología y Parasitología, Facultad de Medicina, UNAM, Mexico City, Mexico.
Frederic CadetPEACCEL, Artificial Intelligence Department, AI for Biologics, Paris, France.ORCID 0000-0002-3568-9595
Rodolfo García-ContrerasDepartamento de Microbiología y Parasitología, Facultad de Medicina, UNAM, Mexico City, Mexico.ORCID 0000-0001-8475-2282

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Options to combat bacterial infections are becoming scarce. We require innovative approaches to enhance the discovery of effective antimicrobials capable of combating bacteria resistant to multiple or all antibiotics. These methods should either directly eliminate resistant bacteria or indirectly influence their viability by inhibiting their virulence or reducing their resistance to antibiotics. One interesting approach is to analyze ancient remedies used to treat bacterial infections, formulate them, and test them against modern microbes. This field has recently been named "ancientbiotics." This approach allows us to leverage centuries of empirical knowledge accumulated, from traditional medicines across various ancient cultures worldwide. The strategy has already yielded promising formulations to combat the ESKAPE group of nosocomial pathogens. Additionally, molecular de-extinction, which involves genome analysis of extinct species to search for useful antimicrobials, such as peptides, offers another avenue. In this review, we compile the antimicrobial effects of ancient remedies and de-extinct molecules known to modern science and discuss possible new strategies to further harness the potential of past remedies and molecules to fight the rise of superbugs.

Indexed as

Anti-Bacterial AgentsBacteriaBacterial InfectionsAnimalsDrug Resistance, BacterialHumansMedicine, TraditionalAnti-Bacterial AgentsAncientbioticsantimicrobialantivirulenceherbal remediesmedicinal plantstraditional medicine

Identifiers

PMID40099865
PMCPMC11980515

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.